Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease

Autor: Jonas Heilskov Graversen, Daniela Berg, Dorle Hennig, Sara A. Ferreira, Claudia Schulte, Walter Maetzler, Marina Romero-Ramos, Anne Panhelainen, Kathrin Brockmann, Holger Jon Møller, Kalpana Shrivastava, Anders Etzerodt, Marlene Christina Nielsen, Sara K. Nissen
Přispěvatelé: Helsinki One Health (HOH), Institute of Biotechnology
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
cognition
POLARIZATION
alpha-synuclein
Regular Issue Articles
Systemic inflammation
Monocytes
0302 clinical medicine
Parkinson Disease/complications
alpha‐
CD163 antigen
Research Articles
Microglia
Neurodegeneration
Parkinson Disease
INFLAMMATORY PROFILE
alpha‐synuclein
medicine.anatomical_structure
Neurology
alpha-Synuclein
Female
medicine.symptom
complications [Parkinson Disease]
Research Article
T-TAU
IMMUNE
sCD163
Antigens
Differentiation
Myelomonocytic
Receptors
Cell Surface
Proinflammatory cytokine
MICROGLIA
03 medical and health sciences
synuclein
Immune system
Antigens
CD
medicine
Humans
ddc:610
Innate immune system
Amyloid beta-Peptides
INTERLEUKIN-15
IDENTIFICATION
business.industry
Monocyte
3112 Neurosciences
biomarkers
ACTIVATION MARKER
medicine.disease
Peptide Fragments
030104 developmental biology
CELLS
Immunology
Neurology (clinical)
business
SCAVENGER RECEPTOR CD163
CD163
030217 neurology & neurosurgery
Zdroj: Movement disorders 36(4), 963-976 (2021). doi:10.1002/mds.28424
Movement Disorders
Nissen, S K, Ferreira, S A, Nielsen, M C, Schulte, C, Shrivastava, K, Hennig, D, Etzerodt, A, Graversen, J H, Berg, D, Maetzler, W, Panhelainen, A, Møller, H J, Brockmann, K & Romero-Ramos, M 2021, ' Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease ', Movement Disorders, vol. 36, no. 4, pp. 963-976 . https://doi.org/10.1002/mds.28424
Popis: BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disorder with a significant immune component, as demonstrated by changes in immune biomarkers in patients' biofluids. However, which specific cells are responsible for those changes is unclear because most immune biomarkers can be produced by various cell types.OBJECTIVES: The aim of this study was to explore monocyte involvement in PD.METHODS: We investigated the monocyte-specific biomarker sCD163, the soluble form of the receptor CD163, in cerebrospinal fluid (CSF) and serum in two experiments, and compared it with other biomarkers and clinical data. Potential connections between CD163 and alpha-synuclein were studied in vitro.RESULTS: CSF-sCD163 increased in late-stage PD and correlated with the PD biomarkers alpha-synuclein, Tau, and phosphorylated Tau, whereas it inversely correlated with the patients' cognitive scores, supporting monocyte involvement in neurodegeneration and cognition in PD. Serum-sCD163 increased only in female patients, suggesting a sex-distinctive monocyte response. CSF-sCD163 also correlated with molecules associated with adaptive and innate immune system activation and with immune cell recruitment to the brain. Serum-sCD163 correlated with proinflammatory cytokines and acute-phase proteins, suggesting a relation to chronic systemic inflammation. Our in vitro study showed that alpha-synuclein activates macrophages and induces shedding of sCD163, which in turn enhances alpha-synuclein uptake by myeloid cells, potentially participating in its clearance.CONCLUSIONS: Our data present sCD163 as a potential cognition-related biomarker in PD and suggest a role for monocytes in both peripheral and brain immune responses. This may be directly related to alpha-synuclein's proinflammatory capacity but could also have consequences for alpha-synuclein processing. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Databáze: OpenAIRE
Externí odkaz: